Margherita Turinetto

Via Francesco Nava 31
Milan, 20159, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Neoadjuvant chemotherapy followed by interval surgery versus primary debulking surgery in FIGO stage III-IV epithelial ovarian cancer: A systematic review and meta-analysis.

Neoadjuvant chemotherapy followed by interval surgery versus primary debulking surgery in FIGO stage III-IV epithelial ovarian cancer: A systematic review and meta-analysis.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 18, 2025

PARPi and myeloid neoplasms; the Italian MITO-MaNGO experience based on a multicentric survey.

PARPi and myeloid neoplasms; the Italian MITO-MaNGO experience based on a multicentric survey.

Journal: ESMO open

Published: August 20, 2025

Time tO last ChemotherApy and death in ovaRian cancEr patients: TO CARE/MITO 42 study, a retrospective analysis of italian MITO centers.

Time tO last ChemotherApy and death in ovaRian cancEr patients: TO CARE/MITO 42 study, a retrospective analysis of italian MITO centers.

Journal: Frontiers in oncology

Published: June 05, 2025

Should all advanced BRCA-mutated patients in response to first-line platinum-based chemotherapy receive PARPi + bevacizumab as maintenance therapy?

Should all advanced BRCA-mutated patients in response to first-line platinum-based chemotherapy receive PARPi + bevacizumab as maintenance therapy?

Journal: ESMO open

Published: April 25, 2024

Ovarian clear cell carcinoma: open questions on the management and treatment algorithm.

Ovarian clear cell carcinoma: open questions on the management and treatment algorithm.

Journal: The oncologist

Published: March 20, 2024

Corrigendum: Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors.

Corrigendum: Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors.

Journal: Frontiers in oncology

Published: December 18, 2023

BRCA1/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challenges.

BRCA1/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challenges.

Journal: Frontiers in oncology

Published: December 12, 2023

Uterine smooth muscle tumors: a multicenter, retrospective, comparative study of clinical and ultrasound features.

Uterine smooth muscle tumors: a multicenter, retrospective, comparative study of clinical and ultrasound features.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: December 06, 2023

MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)-Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors-A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study.

MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)-Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors-A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study.

Journal: Cancers

Published: October 31, 2023

MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy.

MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: August 23, 2023

Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors.

Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors.

Journal: Frontiers in oncology

Published: June 25, 2023

Retrospective Analysis of the Correlation of MSI-h/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience.

Retrospective Analysis of the Correlation of MSI-h/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience.

Journal: Cancers

Published: June 10, 2023

Showing 1-12 of 27

Last Updated: 09/26/2026